Increased tumour extracellular pH induced by Bafilomycin A1 inhibits tumour growth and mitosis in vivo and alters 5-fluorouracil pharmacokinetics

European Journal of Cancer

Volumn 39, Issue 4, 2003, Pages 532-540

  McSheehy, P M J ^a,c   Troy, H ^a   Kelland, L R ^a,d   Judson, I R ^a   Leach, M O ^b   Griffiths, J R ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

5FU uptake; 31P MRS; Bafilomycin; PH; Solid tumours

Indexed keywords

BAFILOMYCIN A1; FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PH; CELL PROLIFERATION; CELL STRAIN GH3; CONTROLLED STUDY; DRUG RETENTION; FLOW CYTOMETRY; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON TRANSPORT; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTIFUNGAL; ANTIMETABOLITES, ANTINEOPLASTIC; CELL DIVISION; FLUOROURACIL; HYDROGEN-ION CONCENTRATION; MACROLIDES; MICE; MICE, NUDE; MITOSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; RATS; RATS, WISTAR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0037363443     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00671-8     Document Type: Article

References (43)

1. Stubbs M., McSheehy P.M.J., Griffiths J.R., Bashford C.L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today. 6:2000;15-19.
2. Griffiths J.R. Are cancer cells acidic? Br. J. Cancer. 64:1991;425-427.
3. 31P probes. Br. J. Cancer. 77:1999;873-879.
4. Gatenby R.A. The potential role of transformation-induced metabolic changes in tumour-host interaction. Cancer Res. 55:1995;4151-4155.
5. Stubbs M., Rodrigues L.M., Howe F.A.et al. The metabolic consequences of a reversed pH gradient in rat tumours. Cancer Res. 54:1994;4011-4016.
6. +-ATPases are functionally expressed in plasma membranes of human tumour cells. Am J Physiol 1993, 265 (Cell Physiol. 34), C1015-C1029.
7. Martinez-Zaguilan R., Seftor E.A., Seftor R.E.B., Chu Y.-W., Gillies R.J., Hendrix M.J.C. Acidic pH enhances the invasive behaviour of human melanoma cells. Clin. Exp. Metastasis. 14:1996;176-186.
8. Griffiths L., Dachs G.U., Bicknell R., Harris A.L., Stratford I.J. The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumour cells grown in vitro and in vivo. Cancer Res. 57:1996;570-572.
9. Gerweck L.E. Tumour pH: implications for treatment and novel drug design. Semin Radiat. Oncol. 8:1998;176-182.
10. Bowman E.J., Siebers A., Altendorf K. Bafilomycins. a class of inhibitors of membrane ATPases from microorganaisms, animal cells and plant cells Proc. Natl. Acad. Sci. 85:1988;7972-7976.
11. +)-ATPases. FEBS Letts. 440:1998;258-263.
12. Murakami T., Shibuya I., Ise T.et al. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistance. Int. J. Cancer. 93:2001;869-874.
13. +-ATPase suppresses proliferation of cultured cells. J. Cell Physiol. 157:1993;445-452.
14. Hall T.J. Cytotoxicity of vacuolar H(+)-ATPase inhibitors to UMR-106 rat osteoblasts. an effect on iron uptake into cells? Cell Biol. Int. 8:1994;189-193.
15. 1 induces apoptosis in PC12 cells independently of intracellular pH. FEBS Letts. 387:1996;61-66.
16. +-ATPase in human pancreatic cancer. Brit. J. Cancer. 73:1996a;1511-1517.
17. +-adenosine triphosphatease activity in multidrug resistance in HL60 cells. J. Natl. Cancer Inst. 81:1991;098-1102.
18. +-ATPase in drug-resistant human breast carcinoma cell lines. Biochem. Pharm. 57:1999;1037-1046.
19. Ohta T., Arakawa H., Futagami F.et al. A new strategy for the therapy of pancreatic cancer by proton pump inhibitor. Gan to Kagaku Ryoho. 23:1996b;1660-1664.
20. Werner G., Hagenmaier H., Albert K., Kohlshorn H., Drautz H. Tetrahedron Lett. 24:1983;5193.
21. Robinson S.P., Rodrigues L.M., McSheehy P.M.J., Howe F.A., Griffiths J.R. The response to carbogen breathing in experimental tumour models monitored by gradient-recalled echo magnetic resonance imaging. Br. J. Cancer. 75:1997;1000-1006.
22. Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P., Harrap K.R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer. 59:1989;527-534.
23. Sharp S.Y., Rowlands M.G., Jarman M., Kelland L.R. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and-resistant human ovarian carcinoma cell lines. Br J. Cancer. 70:1994;409-414.
24. 31P-MRS in rat tumours. increased uptake and cytotoxicity induced by carbogen breathing in GH3 prolactinomas Br. J. Cancer. 75:1997;62-68.
25. Monks A., Scudiero D., Skehan P.et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tmour cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
26. O'Neill C.F., Koberle B., Masters J.R.W., Kelland L.R. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br. J. Cancer. 81:1999;1294-1303.
27. Sharma R., Adam E., Schumacher U. The action of 5-fluorouracil on human HT29 colon cancer cells grown in SCID mice. mitosis, apoptosis and cell differentiation Br. J. Cancer. 76:1997;1011-1016.
28. McSheehy P.M.J., Robinson S.P., Ojugo A.S.E.et al. Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumours. a magnetic resonance study in vivo Cancer. Res. 58:1998;1185-1194.
29. McSheehy P.M.J., Prior M.J.W., Griffiths J.R. Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br. J. Cancer. 60:1988;303-309.
30. Bergmeyer H.U. Methods of Enzymatic Analysis. 1974;Verlag Chemie, Weinheim, Deutschland.
31. 31P magnetic resonance spectroscopy. Eur. J. Cancer. 33:1997;2418-2427.
32. Ojugo A.S.E., McSheehy P.M.J., Stubbs M.et al. Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br. J. Cancer. 77:1998;873-879.
33. Warburg, O. On the Metabolism of Tumours in the Body (F. Dickens, English translation). London: Arnold Constable, 1930, pp. 254-270.
34. +-ATPase have altered rates of protein turnover. Arch. Biochem & Biophys. 314:1994;268-275.
35. +-ATPase of osteoclasts with bone antiresorptive activity. J. Med. Chem. 41:1998;1568-1573.
36. Podo F. Tumour phospholipid metabolism. NMR Biomed. 12:1999;413-439.
37. Nishihara T., Akifusa S., Koseki T., Kato S., Muro M., Hanada N. Specific inhibitors of vacuolar ATPases induce apoptotic cell death. Biochem. Biophys. Res. Comm. 212:1995;255-262.
38. Leist M., Jäättelä M. Four deaths and a funeral. from caspases to alternative mechanisms Nature Reviews. 2:2001;1-10.
39. 1 arrest and determine the cellular response to Rapamycin. Cancer Res. 61:2001;3373-3381.
40. Yin D., Tamaki N., Kokunai T., Yasuo K., Yonezawa K. Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. J. Clin. Neuroscience. 6:1999;326-331.
41. Wolf W., Waluch V., Presant C. A. Non-invasive19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed. 11:1998;380-387.
42. Raghunand N., He X., van Sluis R.et al. Enhancement of chemotherapy by manipulation of tumor pH. Br. J. Cancer. 80:1999;1005-1011.
43. Kozin S.V., Shkarin P., Gerweck L.E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 61:2001;4740-4743.